| Literature DB >> 30513728 |
Vladimir Milovanovic1, Dejan Bisenic2, Branko Mimic3, Bilal Ali4, Massimiliano Cantinotti5, Ivan Soldatovic6, Irena Vulicevic7, Bruno Murzi8, Slobodan Ilic9.
Abstract
OBJECTIVE(S): Modified ultrafiltration has gained wide acceptance as a powerful tool against cardiopulmonary bypass morbidity in pediatric cardiac surgery. The aim of our study was to assess the importance of modified ultrafiltration within conditions of contemporary cardiopulmonary bypass characteristics.Entities:
Keywords: clinical outcomes; conventional ultrafiltration; modified ultrafiltration; pediatric cardiac surgery
Year: 2018 PMID: 30513728 PMCID: PMC6306792 DOI: 10.3390/jcm7120498
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.241
Demographics and operative data.
| MUF | Non MUF | ||
|---|---|---|---|
|
| 49 | 49 | |
| Age (days) | 160 ± 159 | 196 ± 169 | 0.23 |
| Weigh (kg) | 6.2 ± 2.9 | 6.7 ± 3.0 | 0.38 |
| BSA (m2) | 0.3 ± 0.2 | 0.3 ± 0.1 | 0.60 |
| Minimum core temperature (°C) | 32.9 ± 4.3 | 34.2 ± 2.1 | 0.15 |
| CPB time (min) | 101.4 ± 46.8 | 91.6 ± 47.3 | 0.24 |
| X-CL time (min) | 51.4 ± 27.3 | 52.6 ± 26.1 | 0.83 |
| Aristotle basic score | 7.6 ± 2.1 | 7.4 ± 2.1 | 0.64 |
| LW cohort | |||
|
| 26 | 23 | |
| Age (days) | 44 ± 31 | 45 ± 32 | 0.81 |
| Weigh (kg) | 3.9 ± 0.8 | 4.1 ± 0.7 | 0.55 |
| BSA (m2) | 0.2 ± 0 | 0.2 ± 0 | 0.72 |
| Minimum core temperature (°C) | 32.0 ± 5.5 | 33.8 ± 2.3 | 0.34 |
| CPB time (min) | 111.9 ± 47.1 | 109.9 ± 60.0 | 0.63 |
| X-CL time (min) | 54.8 ± 28.1 | 61.6 ± 31.4 | 0.96 |
| Aristotle basic score | 8.4 ± 2.4 | 8.3 ± 2.1 | 0.82 |
MUF—modified ultrafiltration; N—number; LW—lower weight; BSA—body surface area; CPB—cardiopulmonary bypass; X-CL—cross clamp.
CPB and ultrafiltration data.
| MUF | Non MUF | ||
|---|---|---|---|
|
| 49 | 49 | |
| CPB Prime volume (mL/kg) | 76.7 ± 31.2 | 64.9 ± 24.4 | 0.04 |
| Ultrafiltrate volume (mL/kg) | 127.7 ± 66.5 | 98.3 ± 42.7 | 0.05 |
| Fluid added during CPB (mL/kg) | 97.4 ± 50.2 | 89.50 ± 52.3 | 0.44 |
| PRBC’s added during CPB (mL/kg) | 26.8 ± 12.2 | 33.7 ± 22.3 | 0.45 |
| Urine output during CPB (mL/kg) | 8.5 ± 13.5 | 7.0 ± 14.5 | 0.14 |
| LW cohort | |||
|
| 26 | 23 | |
| CPB Prime volume (mL/kg) | 97.7 ± 26.1 | 81.6 ± 21.7 | 0.01 |
| Ultrafiltrate volume (mL/kg) | 170.9 ± 57.6 | 133.8 ± 33.4 | 0.05 |
| Fluid added during CPB (mL/kg) | 111.5 ± 36.5 | 120.4 ± 52.0 | 0.49 |
| PRBC’s added during CPB (mL/kg) | 33.5 ± 13.9 | 42.4 ± 43.8 | 0.97 |
| Urine output during CPB (mL/kg) | 10.0 ± 14.7 | 9.4 ± 18.9 | 0.42 |
CPB—cardiopulmonary bypass; PRBC’s—packed red blood cells.
Hematocrit data.
| MUF | Non MUF | ||
|---|---|---|---|
|
| 49 | 49 | |
| Baseline (%) | 35.3 ± 6.5 | 33.4 ± 4.1 | 0.08 |
| Cross clamp on (%) | 31.6 ± 3.4 | 31.7 ± 2.6 | 0.8 |
| Cross clamp off (%) | 32.2 ± 4.1 | 33.6 ± 3.0 | 0.06 |
| Post CUF/MUF (%) | 40.8 ± 3.8 | 37.1 ± 4.9 | 0.001 |
| ICU admission (%) | 39.7 ± 5.2 | 39.2 ± 4.1 | 0.58 |
| 4 h ICU (%) | 38.7 ± 4.8 | 38.1 ± 3.9 | 0.5 |
| 12 h ICU (%) | 37.8 ± 4.4 | 35.3 ± 4.4 | 0.08 |
| 24 h ICU (%) | 35.4 ± 5.1 | 33.3 ± 3.9 | 0.04 |
| Delta HCT 1–8 | 0.12 ± 7.3 | −0.64 ± 5.0 | 0.58 |
| LW cohort | |||
|
| 26 | 23 | |
| Baseline % | 34.4 ± 6.5 | 33.0 ± 4.8 | 0.41 |
| Cross clamp on (%) | 31.1 ± 3.9 | 31.3 ± 2.1 | 0.76 |
| Cross clamp off (%) | 32.6 ± 4.3 | 33.3 ± 1.9 | 0.47 |
| Post CUF/MUF (%) | 39.7 ± 3.7 | 37.2 ± 4.9 | 0.04 |
| ICU admission (%) | 38.6 ± 5.7 | 39.2 ± 4.8 | 0.69 |
| 4 h ICU (%) | 37.5 ± 4.6 | 38.0 ± 4.3 | 0.67 |
| 12 h ICU (%) | 37.5 ± 3.7 | 35.9 ± 3.0 | 0.11 |
| 24 h ICU (%) | 35.0 ± 4.0 | 33.0 ± 3.6 | 0.09 |
| Delta HCT 1-8 | −0.16 ± 6.67 | −0.62 ± 5.06 | 0.79 |
CUF—conventional ultrafiltration; MUF—modified ultrafiltration; ICU—intensive care unit; HCT—hematocrit.
Figure 1Hematocrit data for overall cohort—Ao Cl on—cross clamp on; Ao Cl off—cross clamp off; MUF—modified ultrafiltration; CUF—conventional ultrafiltration, ICU—intensive care unit.
Figure 2Hematocrit data for lower weight cohort—Ao Cl on—cross clamp on; Ao Cl off—cross clamp off; MUF—modified ultrafiltration; CUF—conventional ultrafiltration, ICU—intensive care unit.
Postoperative transfusion frequency.
| MUF | Non MUF | ||
|---|---|---|---|
|
| 49 | 49 | |
| PRBC | 22 (44.9%) | 36 (73.5%) | 0.01 |
| FFP | 17 (34.7%) | 8 (16.3%) | 0.04 |
| Cryo | 11 (22.5%) | 7 (14.3%) | 0.36 |
| PLT | 8 (16.3%) | 5 (10.3%) | 0.46 |
| LW cohort | |||
|
| 26 | 23 | |
| PRBC | 18 (69.3%) | 21 (91.3%) | 0.07 |
| FFP | 12 (46.1%) | 5 (21.7%) | 0.05 |
| Cryo | 9 (34.7%) | 7 (30.4%) | 1.00 |
| PLT | 6 (23.1%) | 5 (21.7%) | 0.52 |
PRBC—packed red blood cells, FFP—fresh frozen plasma, Cryo—cryoprecipitate, PLT—platelets.
Transfusion data, post-op labs, and chest tube output.
| MUF | Non MUF | ||
|---|---|---|---|
|
| 49 | 49 | |
| Peri-op PRBC (mL/kg) | 28.33 ± 20.15 | 17.77 ± 12.79 | 0.01 |
| Peri-op FFP (mL/kg) | 14.8 ± 15.6 | 9.1 ± 3.2 | 0.43 |
| Peri-op cryo (mL/kg) | 9.8 ± 5.2 | 8.5 ± 6.3 | 0.30 |
| Peri-op platelets (mL/kg) | 11.7 ± 6.3 | 4.6 ± 1.2 | 0.09 |
| ICU platelet count (× 103/uL) | 115.3 ± 33.1 | 127.6 ± 44.5 | 0.12 |
| INR | 1.7 ± 0.4 | 1.8 ± 0.3 | 0.69 |
| Fibrinogen (g/L) | 2.0 ± 0.8 | 1.7 ± 0.6 | 0.14 |
| PT (sec) | 21.0 ± 4.9 | 21.8 ± 3.5 | 0.36 |
| APTT (sec) | 39.1 ± 14.4 | 41.40 ± 10.0 | 0.37 |
| Chest tube output (mL/kg) | 26.6 ± 21.6 | 25.2 ± 21.4 | 0.60 |
| LW cohort | |||
|
| 26 | 23 | |
| Peri-op PRBC | 31.3 ± 21.0 | 23.3 ± 13.8 | 0.16 |
| Peri-op FFP (mL/kg) | 17.1 ± 17.8 | 9.4 ± 3.4 | 0.55 |
| Peri-op cryo (mL/kg) | 10.6 ± 4.8 | 9.0 ± 6.7 | 0.25 |
| Peri-op platelets (mL/kg) | 14.8 ± 4.0 | 4.7 ± 1.4 | 0.01 |
| ICU platelet count (× 103/uL) | 116.8 ± 32.9 | 130.4 ± 54.4 | 0.29 |
| INR | 1.9 ± 0.5 | 1.9 ± 0.3 | 0.80 |
| Fibrinogen (g/L) | 1.8 ± 0.8 | 1.6 ± 0.6 | 0.46 |
| PT (sec) | 22.6 ± 5.7 | 22.8 ± 3.5 | 0.89 |
| APTT (sec) | 44.9 ± 13.3 | 45.9 ± 8.9 | 0.75 |
| Chest tube output (mL/kg) | 33.8 ± 22.7 | 30.5 ± 23.6 | 0.47 |
PRBC—packed red blood cells; FFP—fresh frozen plasma; Cryo—cryoprecipitate; INR—international normalized ratio; PT—prothrombin time; APTT—activated partial thromboplastin time.
Effects on gas exchange capacity and ventilation time.
| MUF | Non MUF | ||
|---|---|---|---|
| P (A−a) O2 1 | 0.55 ± 0.38 | 0.59 ± 0.29 | 0.52 |
| P (A−a) O2 2 | 0.44 ± 0.21 | 0.44 ± 0.21 | 0.92 |
| P (A−a) O2 3 | 0.53 ± 0.24 | 0.50 ± 0.23 | 0.53 |
| P (A−a) O24 | 0.57 ± 0.23 | 0.58 ± 0.22 | 0.70 |
| Delta P (A−a) O2 1–4 | 0.39 ± 0.13 | 0.30 ± 0.20 | 0.65 |
| OI 1 | 4.5 ± 5.4 | 3.3 ± 3.4 | 0.21 |
| OI 2 | 4.5 ± 4.4 | 4.1 ± 3.2 | 0.53 |
| OI 3 | 3.4 ± 3.4 | 3.5 ± 3.6 | 0.83 |
| OI 4 | 3.9 ± 4.1 | 2.9 ± 1.5 | 0.59 |
| Delta OI 1–4 | 2.7 ± 3.1 | 2.1 ± 2.6 | 0.39 |
| RI 1 | 2.3 ± 3.2 | 1.5 ± 2.3 | 0.32 |
| RI 2 | 2.2 ± 2.7 | 2.0 ± 1.7 | 0.90 |
| RI 3 | 1.8 ± 2.5 | 1.8 ± 2.1 | 0.48 |
| RI 4 | 1.4 ± 2.2 | 1.4 ± 2.7 | 0.72 |
| Delta RI 1–4 | 0.13 ± 4.39 | −0.54 ± 2.93 | 0.28 |
| Ventilation time (h) | 46.5 ± 99.3 | 33.7 ± 55.1 | 0.53 |
| LW cohort | |||
| P (A−a) O2 1 | 0.46 ± 0.31 | 0.50 ± 0.24 | 0.68 |
| P (A−a) O2 2 | 0.40 ± 0.21 | 0.32 ± 0.16 | 0.14 |
| P (A−a) O2 3 | 0.47 ± 0.22 | 0.34 ± 0.18 | 0.05 |
| P (A−a) O24 | 0.50 ± 0.22 | 0.46 ± 0 .20 | 0.55 |
| Delta P (A−a) O2 (1–4) | 0.05 ± 0.35 | 0.18 ± 0.31 | 0.15 |
| OI 1 | 5.9 ± 6.8 | 4.5 ± 4.5 | 0.57 |
| OI 2 | 4.7 ± 3.3 | 5.1 ± 3.7 | 0.67 |
| OI 3 | 3.5 ± 2.5 | 5.3 ± 4.4 | 0.11 |
| OI 4 | 3.3 ± 1.7 | 3.2 ± 1.5 | 0.96 |
| Delta OI (1–4) | 3.4 ± 1.2 | 3.8 ± 2.1 | 0.41 |
| RI 1 | 2.8 ± 3.4 | 2.1 ± 2.9 | 0.61 |
| RI 2 | 2.4 ± 2.7 | 2.9 ± 1.8 | 0.13 |
| RI 3 | 2.0 ± 2.6 | 2.9 ± 2.5 | 0.02 |
| RI 4 | 1.8 ± 2.2 | 1.9 ± 2.4 | 0.50 |
| Delta RI (1–4) | 4.57 ± −0.75 | 3.97 ± −2.30 | 0.41 |
| Ventilation time (h) | 82.1 ± 123.8 | 75.0 ± 130.4 | 0.84 |
P (A−a) O2—alveolar-arterial oxygen pressure difference; OI—oxygen index; RI—respiratory index.
Vasoactive inotrope scores, ICU, and hospital length of stay.
| MUF | Non MUF | ||
|---|---|---|---|
|
| 49 | 49 | |
| IS 1 (post filtration) | 7.1 ± 5.7 | 6.4 ± 9.2 | 0.10 |
| IS 2 (ICU admission) | 7.1 ± 5.7 | 6.7 ± 10.7 | 0.20 |
| IS 3 (4 h) | 7.3 ± 6.0 | 6.7 ± 10.7 | 0.11 |
| IS 4 (12 h) | 6.6 ± 5.4 | 6.5 ± 10.7 | 0.29 |
| IS 5 (24 h) | 5.9 ± 5.3 | 6.4 ± 10.8 | 0.64 |
| Delta IS (1–5) | 1.01 ± 2.72 | 0.03 ± 11.3 | 0.56 |
| ICU LOS (days) | 6.8 ± 10.2 | 5.0 ± 7.0 | 0.58 |
| Hospital LOS (days) | 15.4 ± 14.0 | 14.3 ± 14.2.0 | 0.43 |
| LW cohort | |||
|
| 26 | 23 | |
| IS 1 | 8.2 ± 6.2 | 6.7 ± 3.4 | 0.19 |
| IS 2 | 8.1 ± 6.3 | 9.3 ± 14.8 | 0.41 |
| IS 3 | 8.6 ± 6.8 | 9.3 ± 14.8 | 0.16 |
| IS 4 | 7.5 ± 6.3 | 9.3 ± 14.8 | 0.69 |
| IS 5 | 7.0 ± 6.4 | 9.9 ± 14.8 | 0.37 |
| Delta IS (1–5) | 1.0 ± 1.5 | −2.5 ± 12.8 | 0.17 |
| ICU LOS (days) | 11.2 ± 12.5 | 8.9 ± 9.1 | 0.83 |
| Hospital LOS (days) | 23.8 ± 14.8 | 24.2 ± 16.1 | 0.59 |
IS—inotropic score; ICU—intensive care unit; LOS—length of stay.